Cardiovascular Drugs
•37 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (37)
%
| Company | Market Cap | Price |
|---|---|---|
|
Incretin/diabetes and cardiometabolic therapies position Lilly in the Cardiovascular Drugs space.
|
$789.93B |
$833.49
-2.86%
|
|
The CVRM/metabolic portfolio (Farxiga, Baxdrostat with cardiovascular implications) positions AZN in Cardiovascular Drugs.
|
$262.04B |
$84.53
-1.28%
|
|
Leqvio (inclisiran) positions Novartis in Cardiovascular Drugs via siRNA therapy.
|
$252.00B |
$130.00
|
|
Repatha and other cardiovascular-focused therapies place Amgen in the Cardiovascular Drugs category.
|
$156.00B |
$290.13
-2.04%
|
|
Pfizer markets cardiovascular therapies (e.g., Eliquis) and other heart-disease drugs.
|
$137.19B |
$24.09
-0.15%
|
|
Camzyos and associated cardiovascular/anticoagulant programs place BMY in the Cardiovascular Drugs space.
|
$89.46B |
$43.96
-1.83%
|
|
UTHR's core PAH/PH-ILD prostacyclin therapies drive the revenue base, including Tyvaso DPI, Nebulized Tyvaso, Remodulin/Remunity, and Orenitram.
|
$19.85B |
$440.00
-1.27%
|
|
Selatogrel (emergency cardiovascular treatment) and related assets place Viatris in cardiovascular drug opportunities.
|
$11.17B |
$9.52
-0.42%
|
|
Mosliciguat is an inhaled sGC activator for PH-ILD, a cardiovascular/respiratory drug indication.
|
$10.90B |
$16.04
-0.50%
|
|
Cytokinetics' lead and pipeline programs are focused on cardiovascular conditions (HCM, HFrEF, HFpEF), aligning with the Cardiovascular Drugs investable theme.
|
$7.17B |
$60.04
-0.38%
|
|
Plozasiran targets triglyceride-rich lipoproteins and cardiometabolic risk, aligning with cardiovascular/heart/metabolic drug development.
|
$4.89B |
$35.41
-1.64%
|
|
SRK-439 targets cardiometabolic health (lean-mass preservation with GLP-1 therapies), fitting Cardiovascular Drugs.
|
$3.75B |
$39.46
-3.94%
|
|
The lead asset targets cardiovascular disease by lowering LDL-C and Lp(a), placing it in the Cardiovascular Drugs category.
|
$3.42B |
$37.05
+10.86%
|
|
Cardiovascular drugs: targeting inflammatory cardiovascular conditions such as recurrent pericarditis (ARCALYST) and related pipeline assets.
|
$2.76B |
$37.89
-0.58%
|
|
Targeting hypertension (a cardiovascular indication) places Mineralys under 'Cardiovascular Drugs'.
|
$2.75B |
$42.16
+6.98%
|
|
YUTREPIA and Liquidia's cardiovascular prostacyclin program place the company in the Cardiovascular Drugs category.
|
$1.98B |
$23.19
-5.19%
|
|
Program targets cardiovascular inflammation (ASCVD) via IL-6 inhibition, aligning with Cardiovascular Drugs.
|
$1.23B |
$47.75
|
|
Focus on renal/cardiovascular/metabolic diseases places Maze in Cardiovascular Drugs as part of the CVRM space.
|
$1.20B |
$27.43
-4.62%
|
|
GIAPREZA is a cardiovascular drug marketed by Innoviva's Specialty Therapeutics platform; direct product sales in this category.
|
$1.09B |
$17.35
-0.91%
|
|
Sotagliflozin and related assets target cardiovascular indications (heart failure, hypertrophic cardiomyopathy), placing Lexicon in the cardiovascular drug space.
|
$541.14M |
$1.49
-10.24%
|
|
Product portfolio focuses on cardiovascular risk reduction and LDL-C lowering, classifying the company under Cardiovascular Drugs.
|
$501.44M |
$2.53
+2.85%
|
|
VASCEPA/icosapent ethyl is a cardiovascular drug indicated for reduction of major adverse cardiovascular events; core product in Amarin's portfolio.
|
$374.93M |
$18.23
-5.35%
|
|
Lead programs address cardiovascular conditions, aligning with Cardiovascular Drugs.
|
$341.60M |
$2.10
-5.19%
|
|
TX45 is being developed for pulmonary hypertension and related cardiovascular conditions.
|
$299.13M |
$16.02
-6.10%
|
|
Zerlasiran lowers Lp(a) and addresses cardiovascular risk, aligning with the Cardiovascular Drugs category.
|
$235.84M |
$5.00
-7.41%
|
|
Zerlasiran targets cardiovascular risk factors (high Lp(a)); cardiovascular drug category relevance.
|
$226.72M |
$1.60
|
|
Therapies targeting cardiovascular diseases place Lexeo in the cardiovascular drug category.
|
$219.76M |
$6.62
-1.05%
|
|
Pulmonary arterial hypertension (PAH) is a cardiovascular/vascular indication, and IKT-001Pro targets PAH.
|
$120.43M |
$1.62
|
|
Etripamil is a cardiovascular drug (calcium channel blocker) aimed at PSVT and AFib-RVR, making Cardiovascular Drugs the core product category.
|
$106.39M |
$1.99
-5.24%
|
|
Lead candidate CardiolRx is a cardiovascular drug targeting myocarditis and recurrent pericarditis, placing Cardiol Therapeutics in the Cardiovascular Drugs investable theme.
|
$73.00M |
$1.04
-4.59%
|
|
Sabizabulin is positioned for cardiovascular disease (ASCVD), justifying the Cardiovascular Drugs tag as a core therapeutic category.
|
$54.68M |
$3.73
+3.61%
|
|
Pipeline program includes cardiovascular disease indications (e.g., DMD cardiomyopathy), aligning with the 'Cardiovascular Drugs' theme.
|
$51.62M |
$3.45
-2.27%
|
|
GTx-104 is a novel cardiovascular drug formulation (nimodipine) for aSAH, placing Grace Therapeutics in the Cardiovascular Drugs category.
|
$41.35M |
$2.99
-1.01%
|
|
TENX's core program centers on levosimendan (TNX-103) for PH-HFpEF, a cardiovascular drug, aligning with the Cardiovascular Drugs tag.
|
$30.95M |
$7.46
-4.85%
|
|
Tecarfarin targets cardiovascular indications (LVAD and ESKD+AFib), consistent with Cardiovascular Drugs.
|
$27.59M |
$14.03
+0.14%
|
|
Arbli targets hypertension and cardiovascular risk reduction, aligning with Cardiovascular Drugs.
|
$9.20M |
$0.70
-6.52%
|
|
Medicure’s direct prescription cardiovascular drugs (AGGRASTAT and ZYPITAMAG) place it squarely in the Cardiovascular Drugs category.
|
$7.83M |
$0.75
|
Loading industry metrics...
Loading comparison data...
